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Abstract
This study was an extension of a previous study done by Spiegel,
Bruce, Falkin-Gregg, and Nuzzarello (in press), the latter of
which tested whether cognitive behavior therapy assisted
alprazolam discontinuation in panic disorder patients.

The focus

of cognitive behavior therapy in relation to benzodiazepine
discontinuation placed great emphasis on changing cognitive
biases during

th~

treatment process.

The present study

investigated whether groups differed on cognitive factors
associated with panic disorder (e,g. catastrophic
misinterpretations, sensitivity to bodily sensations, and a
feeling of lack of control over emotions and situations) and
whether that change predicted discontinuation.

The results

showed the alprazolam plus cognitive behavior therapy group had
significantly greater cognitive change compared to the alprazolam
only group.

Furthermore, cognitive change, in addition to

overall anxiety, was involved in predicting which subjects were
able to successfully discontinue alprazolam treatment.
Implications for benzodiazepine treatment in conjunction with
cognitive behavior therapy are discussed.
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The Implications of Cognitive Change
in the Treatment of Panic Disorder with Agoraphobia
Panic disorder with agoraphobia (PDA) is extremely
debilitating, prohibiting the daily functioning of thousands
of people.

It involves feelings of intense fear in

circumstances when there is nothing to fear.

The disorder

is accompanied by severe attacks of panic which occur out of
the blue for no apparent reason.

Consequently, patients may

develop an intense fear of that particular situation or
circumstance.

This fear facilitates the development of

agoraphobia because patients do whatever they can to prevent
a recurrence of the experience, thereby avoiding many
aspects of everyday life.

According to the Diagnostic and

Statistical Manual (DSM-III-R), symptoms of panic disorder
include "shortness of breath or smothering sensations;
dizziness ... choking ... accelerated heart rate ... shaking;
sweating; nausea ... hotflashes; chest pain or discomfort;
fear of dying; fear of going crazy or doing something
uncontrolled during an attack" (American Psychiatric
Association, 1987, p. 236).
The most widely used treatment for PDA is the
benzodiazepine alprazolam (Xanax).

Numerous studies have

shown that alprazolam effectively controls panic attacks,
allowing patients to resume normal activities (Ballenger,
Graham, Burrows, DuPont, Lesser, Noyles, Pecknold, Rifkin, &
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Swinson, 1988;

Barlow, 1988; Rickels, Schweizer, Weiss, &

Zavodnick, 1993).

For example, Ballenger et ale (1988)

executed a large placebo-controlled study to test the
efficacy of alprazolam in the treatment of PDA.

After three

weeks of alprazolam treatment, 51% of subjects showed marked
improvement and at the eight week point, 41% of subjects
showed moderate improvement.

Alprazolam was found to

effectively decrease the frequency of both spontaneous and
situational'panic attacks, phobic fears, avoidance behavior,
anxiety, and secondary

disabili~y.

Furthermore, the study

revealed a significantly larger dropout rate for subjects in
the placebo group (102/234) as compared to the alprazolam
treated group (21/247).

The authors suggested that lithe

large difference in dropout rates, primarily because of
ineffectiveness of placebo, was itself, a measure of the
efficacy of alprazolam" (p. 419).
Although alprazolam is effective in the acute phase of
treatment, others note that it creates physical dependency
and can be extremely hard to discontinue due to withdrawal
symptoms, such as rebound panic and anxiety (Busto, Sellers,
Naranjo, Cappell, Sanchez-Craig, Sykora, 1986; Fyer,
Liebowitz, Gorman, Campeas, Levin, Davis, Goetz, & Klein,
1987; Noyles, Garvey, Cook, & Suelzer, 1991; Pecknold,
Swinson, Kuch, & Lewis, 1988; Rickels et al., 1993;
Schweizer, Rickels, Case, & Greenblatt, 1990) For example,
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Rickels et al. (1993) reported °a withdrawal syndrome in
almost all of the 27 alprazolam-treated patients.

Also, 33%

of these patients were unable to successfully discontinue
their medication" (p. 61).

Of those who did discontinue,

approximately half relapsed within the following months.
One idea to assist alprazolam discontinuation is to
combine Cognitive Behavior Therapy (CBT) with alprazolam.
CST can be focused on altering features of panic disorder in
order to

fac~litate

the discontinuation process (Barlow,

1988; Beck, 1985; Clark, 1986; Klosko, Barlow, Tassinari,

&

Cerny, 1990; Otto, Pollack, Sachs, Reitzer, Meltzer-Brody, &
Rosenbaum, 1993; Spiegel, Bruce, Falkin-Gregg, & Nuzzarello,
in press).

CBT; places strong emphasis on the personal

management of problematic anxiety through skill development,
education, and systematic exposure to feared stimuli
(Spiegel, et al., in press).

Barlow, Craske, Cerny, and

Klosko (1989) devised a specific form of CBT called Panic
Control Treatment (PCT) which aims at reducing patients'
fear of the bodily sensations which they associate with
panic.

Cognitive change is one area emphasized by CBT and

many have hypothesized that successful discontinuation
requires change in this dimension.

For example, Otto et al.

(1993) reported that 13 of 17 (76%) patients receiving CBT

successfully discontinued benzodiazepine treatment compared
to those receiving only slow taper (four of 16; 25%).

They
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speculated that their intervention "decreased fears and
catastrophic misinterpretations of emergent panic sensations
and withdrawal symptoms ... " (p. 1489).
Patients with PDA suffer from a variety of cognitive
dysfunctions.

Specifically, one dysfunction of the disorder

is the catastrophic misinterpretation of anxiety symptoms or
situations.

When feeling nervous, many patients often

catastrophize about the outcome of their situation (Beck,
1985; Chambless, Caputo, Bright, & Gallager, 1984; Clark,
1986; Goldstein & Chambless, 1918).

Clark (1986) explains

that the stimuli which these patients misinterpret can be
external or internal.

If the original stimuli is external,

such as a ballgame where a panic attack has previously
occurred, then the patient experiences anticipatory anxiety
of having another panic attack in this situation, and thus
avoids the ballgame.

However, the stimuli could also be an

internal bodily sensation, like sweating or trembling.
Here, the sweating will cause anxiety and perhaps the fear
of losing control and having a stroke.

If these bodily

sensations are misinterpreted to be catastrophic, further
anxiety occurs and the cycle continues, resulting in a panic
attack.

As a result, sufferers will avoid situations which

may provoke these internal sensations.
The Agoraphobic Cognitions Questionnaire (ACQ) measures
catastrophic misinterpretations and the way patients predict
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the outcome of events.

The directions instruct the patient

to respond according to how they feel when nervous or
frightened.

It is a 14-item test in which each patient

rates the items on a 5-point scale ranging from 1 (thought
never occurs) to 5 (thought always occurs when I am
nervous).

The ACO is two-factor.

It emphasizes

Social/Behavioral Concerns (i.e. acting foolish, babbling or
talking funny), and Physical Concerns (i.e. heart attack,
going blind}.

Gracely, 1989).

(Chambless, et al., 1984; Chambless &
Chambless et al. (1984) have determined

that the ACQ is internally consistent (Cronbach's alpha

=

.80) and has good test-retest reliability.
Another important cognitive aspect associated with panic
disorder 1s the patients' sensitivity to anxiety sensations
which they feel will inevitably result in catastrophic
situations, such as medical catastrophe, embarrassment, or
death (McNally & Lorenz, 1987; Reiss, Peterson, Gurskey, &
McNally, 1986).

For example, when feeling an increase in

heart rate, a patient may predict a heart attack.

Being

anxiety sensitive, which is prevalent among panic disorder
patients, will cause them to be keenly aware of sensations
and avoid potential anxiety-provoking situations (McNally &
Lorenz, 1987; Reiss et al., 1986).
The Reiss-Epstein-Gursky Anxiety Sensitivity Index (ASI)
is a questionnaire designed specifically to measure the fear
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of bodily sensations so commonly found among panic disorder
patients.

The ASI is a 16-item test which centers on a

variety of aversive consequences which may result from an
anxiety provoking stimuli (i.e. It scares me when my heart
beats rapidly) (Barlow, 1988; McNally & Lorenz, 1987; Reiss

et a1., 1986).

The patient responds on a scale from 0

(strongly disagree) to 5 (strongly agree).

Reiss et a1.

(1986) found tpe ASI to have sound psychometric properties
and an adequate test-retest reliability.

The ASI

distinguishes itself from other,anxiety tests in that it
measures the "fear of anxiety symptoms, rather than the
frequency or the intensity of these symptoms" (McNally &

Lorenz, 1987, p. 4).

Reiss et a1. (1986) claim that the ASI

is specifically correlated with panic disorder and
agoraphobia and is a better predictor of fearfulness
compared to other anxiety scales.
In addition to catastrophic misinterpretations and
sensitivity to bodily sensations, one of the most ubiquitous
features of panic disorder patients is their fear of losing
control.

Patients often feel that when something negative

happens to them, whether it be external or internal, it can
not be stopped or controlled (Barlow, 1988; Craske, Bunt,
Rapee, & Barlow, 1991; Sanderson, Rapee, & Barlow, 1989).
An

empirical example of the role of perceived control was

conducted by Sanderson et al. (1989).

They used C02 to
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induce lightheadedness in twenty panic disorder patients and
compared those who believed they had control over the amount
of C02 they were receiving, and those who did not.

They

found that the group who felt they had control over the
amount of C02 enriched air they were receiving reported a
fewer number of DSM-III-R related panic symptoms, had fewer
catastrophic cognitions, and reported overall less anxiety
than the patients who felt they had no control over the
amount of C02 enriched air they were breathing.

This

suggests that the probability of having a panic attack
decreased as the sense of control increased.
In order to measure patients' perceived level of
emotional control the Emotional Control Questionnaire (ECQ)
was developed (Rapee, Craske, & Barlow, 1989).

The ECQ

consists of a 15 item questionnaire with statements such as,
"I can

con~rol ~he

degree to which I react to particular

situations. When I am put under stress, I am likely to lose
control.

w

The patients respond on a 6-point scale from 0

(Strongly Disagree) to 5 (Strongly Agree).

The ECQ has

proven to have good test-retest reliability, construct
validity, and internal consistency.

Higher scores are an

indication that the patient perceives more control over his
emotions (Rapee, et al., 1989).
While adding CBT to alprazolam treatment has been
successful in facilitating discontinuation, we still do not
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know whether this is predicted by or corresponds with
cognitive change.

Catastrophic misinterpretations, lack of

emotional control, and anxiety sensitivity are just a few of
the cognitive aspects hypothetically involved in panic
disorder.

For example, a patient who becomes less sensitive

to internal sensations during treatment, as measured by the
ASI, may be less likely to catastrophize about these
internal situations which may arise again during the taper
process and·after discontinuation.
beneficial to determine if

It would by very

cogn~tive

change in any of these

areas can predict who successfully discontinues drug
therapy.
The following study is an extension of a study done by
Spiegel, Bruce, Falkin-Gregg, & Nuzzarello (in press) which
compared the combination of CBT and alprazolam to an
alprazolam only group.

The original study involved 20

patients with chronic panic disorder, whose panic attacks
had responded to treatment with alprazolam.

Each subject

underwent slow, flexible drug taper with or without
concurrent cognitive behavior therapy.

Results showed that

85% of the subjects were able to successfully discontinue
pharmacotherapy.

However, during the following three

months, 60% of those who had been tapered with only
supportive medical management (without CBT) relapsed,
compared with none who had received cognitive behavior.

The
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present study attempted to determine: 1) If the addition of
cognitive behavior therapy to alprazolam treatment resulted
in more cognitive change than with the drug alone, and

2)

Is the cognitive change which occurred from pre-treatment to
post-treatment, as measured by the ECO, ASI, and ACO,
involved in predicting successful long-term discontinuation
of a1prazo1am.
It was

pre~cted

that the group receiving both a1prazo1am

and CBT will have more cognitive change than the drug only
group because CBT works at

teac~ing

patients to deal with

somatic sensations and can alter their catastrophic
misinterpretations (Otto et a1., 1993).

It was also

hypothesized that changes in the ACO, ASI, and ECO scores
may be involved in predicting successful vs. unsuccessful
,

discontinuation because these scales emphasize the cognitive
aspects associated With panic disorder.

These results would

support the notion that altering distorted cognitions
prepares sUbjects to deal with the recurring symptoms which
often arise during and after drug taper.
METHOD

Subjects
Subjects met the DSM-III-R criteria for panic disorder
with agoraphobia of at least 6 months duration.

They were

recruited by the University of Illinois Anxiety Disorders
Clinic at Peoria to participate in a alprazo1am

-
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discontinuation study.

Subjects consisted of 4 males and 16

females totaling 20 subjects.

Ages ranged from 26-51 with a

mean age of 38 years.

Design and Procedures
After screening, subjects were stabilized on alprazolam
for a 2 week duration.

Following a two-week baseline

period, subjects were randomly placed into two treatment
groups:alpra~lam

maintenance and taper with supportive

medical management (A-Only, N=lO), or the same treatment
plus cognitive behavior therapy, (A+CBT, N=lO).

The protocol

was approved by the Institutional Review Board of the
college, and all subjects gave informed consent and agreed
to random assignment.

Pharmacotherapy.

Alprazolam maintenance and taper were

carried out identically in both groups and consisted of two
phases: a stable-dose phase, during which subjects were
maintained on therapeutic doses; and a taper phase of
variable length, during which alprazolam was decreased every
7-14 days until either discontinuation was complete or the
subject declined to reduce the dose any further.

During the

pharmacotherapy, the subjects met weekly with a
psychiatrist, who was blind to the particular group
assignment, for supportive medical management.

Taper was

done gradually in attempt to limit withdrawal symptoms.

Cognitive Behavior Therapy.

The alprazolam plus CBT
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group differed solely from the alprazolam only group in that
sUbjects received a form of CBT (Panic Control Treatment)
designed by Barlow and Craske.

It was administered to

subjects individually in 12 weekly sessions in accordance
with written manuals.

The therapy incorporated the

following components: education about panic disorder,
training in slow, diaphragmatic breathing, cognitive
restructuring,. and interoceptive exposure (i.e., exposure to
feared bodily sensations).
Measures
Experienced clinician- and self-ratings were made at pre
treatment baseline (the two weeks following drug
stabilization),: 2 weeks post-treatment (two weeks after the
last successful taper step), and a IS-weeks post-treatment.
The evaluator was blind to the subjects' group aSSignment.
Anxiety sensitiVity.

The Anxiety Sensitivity Index was

used to assess sensitivity to anXiety sensations (ASI, 16
items, 0-80 total score, Reiss et al., 1986).

(See Appendix

A)

Catastrophic Cognitions.

Catastrophic

misinterpretations due to experiencing anxiety were assessed
by the Agoraphobic Cognitions Questionnaire (ACQ, 15 items,
0-5 total average score, Chambless, et al., 1984).

(See

Appendix B)
Emotional Control.

Subjects' beliefs about the control

Cognitive Change
14

they have over anxiety and their emotions was assessed by
the Emotional Control Questionnaire (ECQ, 18 items, 0-75
total sum score; Rapee et al., 1989).
Phobic Avoidance.

(See Appendix C)

Level of agoraphobia rated by each

subject was assessed using the Mobility Inventory for
Agoraphobia (MIA, 27 items, 1-5 total average score;
Chambless, et. aI, 1984).
Depressed MQod.

The Beck Depression Inventory (BDI) was

used to assess level of depression.
and a 0-63 total sum score

(Bec~,

It contains 21 items

Ward, Mendelson, Mock, &

Erbaugh, 1961).
Anxious Mood.

The Hamilton Anxiety Rating Scale consists

of 14 items with a 0-56 total sum score (Hamilton, 1959).
It was used to measure general anxiety.
Panic Attacks and Anticipatory Anxiety.

The Sheehan

Panic and Anticipatory Anxiety Scale (Sheehan, Coleman,
Greenblat, Jones, Levine, Orsulak, Peterson, Schildkraut,
Uzogara, & Watkins, 1984) was used by the clinician to rate
the frequency, intensity, and duration of anticipatory
anxiety and spontaneous, situational, limited symptoms (less
than 4 symptoms), and full panic attacks (greater than or
equal to 4 symptoms).

Self-reports of these same dimensions

were assessed using daily diaries which were administered
two weeks prior to each major assessment point.
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The data of 20 panic disorder patients was reviewed and
analyzed using Analyses of Covariance (ANCOVA) with the pre
treatment scores as the covariate, to check for significant
differences between the two groups at two-weeks post-taper
and 15-week follow up.

In addition, the change in scores on

all measures were computed and analyzed using Stepwise
Logistic Regression (SPSS PC+).

The study also determined

which, if any"measures predicted who successfully
discontinued a1prazo1am treatment.
RESULTS

Results of theANCOVAs are depicted in Table 1 along with
each groups' mean test scores at baseline, two-weeks post
taper and 15-weeks post-taper.

At 2-weeks post-taper, a

significant difference between the two groups existed on the
following measures: Disability (Clinician-Rated Disability
Scales; p<.04), Anticipatory Anxiety Frequency (Sheehan
Panic and Anticipatory Anxiety Scale; p<.02), Catastrophic
Thinking (ACQ; p<.003), and Emotional Control (ECQ; p<.04).
At two-weeks post-taper the a1prazo1am plus CBT group showed
significantly more improvement on everyone of these
measures.

ANCOVAS performed at 15-weeks post-taper revealed

significant differences in Anticipatory Anxiety Intensity
(Sheehan Panic and Anticipatory Anxiety Sca1e;p<.03),
Anxious Apprehension, Anxiety (Hamilton Anxiety Rating
Scale; p<,03), and Depression (Beck Depression Inventory;
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p<.04) as well.

Insert Table 1 about here

Logistic Regression Analyses were used to test if pre
treatment to post-treatment change in any dependent measure
predicted discontinuation outcome.

The entry criteria used

was .05 while the exit criteria was conservatively set at
.10.

Resu1~s

showed that only two variables significantly

predicted the outcome.

The

pre~treatment

to post-treatment

change in the ASI and the Hamilton Anxiety Rating Scale
(HAT) were the two variables which the model retained.
Specifically, the results showed that a pre-treatment to
post-treatment decrease in scores on the ASI and the HAT
predicted successful discontinuation whereas no change
predicted failure.

The combination of the two correctly

classified 85% of patients.
The major goal of the regression model was to predict
group membership, which did successfully occur.

The Model

Chi Square was used to test the significance of the model
and was significant at .0008.

In addition to the predictive

value of the ASI and the HAT, when the ASI was removed, the
ACO and HAT classified 80% of the subjects correctly,
indicating the ACO was also a good predictor of
discontinuation success.

Cognitive Change
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DISCUSSION
As early as two weeks following drug taper, subjects in
the alprazolam only group were showing significantly
different scores than the combination group on a variety of
measures.

In particular, the results confirmed the proposed

hypothesis that the alprazolam plus CST group would have
significantly more cognitive change than the alprazolam only
condition.

The subjects receiving alprazolam only were

continuing to catastrophize and were more likely to
underestimate perceived levels of control as measured by the
ACO and ECO, respectively.

They also anticipated more

anxiety which had a distinct disabling effect on their
lives.

These differences between the groups at two-weeks

post-taper were the first indications that perhaps the group
receiving CBT experienced a cognitive restructuring, helping
them to deal with the recurring symptoms after drug taper.
In addition to the cognitive differences between the two
groups at two-weeks post-taper, by IS-weeks post-taper the
subjects in the alprazolam only condition were experiencing
an overall anxious mood and a higher level of depression
than the subjects in the combination group.

It appears as

though a cycle developed as the drug only subjects completed
the taper process.

As follow-up progressed without any

cognitive change, they did not know how to deal with the
recurring symptoms, such as rebound panic and anxiety.

As a

..
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result, they began catastrophizing again, became more
anxious, and perceived a lower level of emotional control.
By IS-weeks post-taper, the alprazolam only subjects were
significantly more anxious and depressed.

In addition, 60%

of this group went back on medication.
These results supported the first hypothesis that more
cognitive change would occur in the alprazolam plus CBT
condition than in the alprazolam only group.
change

occu~red

Because this

during treatment, CBT subjects may have been

better prepared to deal with recurring symptoms after
alprazolam was discontinued.

Furthermore, this implies that

CBT is an important factor involved in facilitating
cognitive

restr~cturing

during panic disorder treatment.

The second hypothesis offered that perhaps a lack of
change on the cognitive measures (ASI, ACO, and ECO) during
treatment would be a significant predictor of relapse.
Logistic Regression Analyses partially supported this
hypothesis by revealing that the ASI and the Hamilton
Anxiety Rating Scale (HAT) had significant importance in
determining treatment outcome, despite their uninvolvement
with the first hypothesis.

Change in scores on the ASI and

the HAT were found to be most associated with predicting
successful discontinuation.

Clinically, this means the

patients who were still keenly sensitive to their bodily
sensations and who were experiencing an overall anxious mood

..
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at two-weeks post-taper were the ones who relapsed.
Seemingly, successful discontinuation required cognitive
change in these two areas.
In addition to the role of the ASI, the ACQ, when used
with the HAT, correctly classified the subjects 80% of the
time.
value.

This suggests that the ACQ does have some predictive
Perhaps it was not more strongly correlated with

discontinuatiop success as was predicted because it measures
general catastrophic thinking and the subjects' symptoms
were more specified.

Like this,measure, the ASI also tests

for catastrophic thinking, but it is specific to bodily
sensations.

This proposes that anxiety sensitivity is a

target point that needs to be addressed when treating panic
disorder patients, either through CST or another means.
other target point is anxious mood.

The

At two-weeks post

taper, the subjects who were still experiencing a general
anxiety and edginess, in addition to being anxiety
sensitive, were likely to go back on alprazolam treatment.
Although this hypothesis was only partially supported,
the results and implications are encouraging.

First, the

findings imply that CST is responsible for the significant
decrease in anxiety sensitivity as reflected by the lower
scores on the ASI for the SUbjects in the combination group
compared to the alprazolam only subjects.

While this study

does imply this correlation, further research is necessary
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to conclude the implication.

One recommendation is to do

the same type of discontinuation study using a normal
version of CST and a form of CST which is controlled for all
else except anxiety sensitivity.

This research could

investigate the existence of the correlation between CST and
anxiety sensitivity suggested by this study.
Another interesting result revealed that four alprazolam
only subjects showed a decrease in scores on the ASI and the
HAT, and successfully discontinued medication.
previous suggestions, this

impl~es

Unlike

that there may be other

ways, besides structured CST, to alter cognitions and
anxiety during benzodiazepine treatment.

Perhaps, a self

help mechanism which employs relaxation training and
cognitive restructuring would be just as effective as full
blown CBT.

The fact that four patients did their own CST

without any prior instruction proposes that changing
cognitions and anxious mood may be considerably less complex
than previously expected.

This study opens new avenues

regarding effective agencies for altering dysfunctional
cognitions.

Further research can be aimed at looking for

other mechanisms by which to alter the dysfunctional
cognitions of panic disorder patients.
Surprisingly, although change in ASI predicted relapse,
it failed to show significance and between group differences
at either two-weeks post-taper or IS-weeks post-taper as was

..
Cognitive Change
21

predicted, although the differences were very close to
conventional levels at .09 and .08, respectively.

One

possible explanation for this is that by 15-weeks post
taper, 60% of the drug only group went back on alprazolam.
Therefore, the benzodiazepine could have been alleviating
the sensitivity to the physical symptoms which the ASI
specifically tests.

The subjects most likely were not

feeling a rapip heart beat, as a result, they may have been
temporarily -less fearful.
problem with the study.

While unavoidable, this was one
It was, impossible to get a score on

the ASI which accurately reflected the differences between
the two groups when so many subjects went back on
medication.

However, the fact that 60% went back on

alprazolam simply validates the importance of cognitive
restructuring.
Another problem with the study is that it lies upon the
assumption that cognitive change will be accurately
represented by the ACQ, ASI, and ECQ.

These measurements

have proven to be valid in assessing the cognitive
symptomatology of panic disorder (Chambless, et al., 1984;
McNally & Lorenz, 1987; Rapee et aI, 1989) however, the
specific cognitive change may not always be accurately
measured or indicated by the subjects' self report.

In

addition, while this study found cognitive change to be an
essential component for panic disorder treatment, many other

..
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factors can be responsible for unsuccessful discontinuation
or relapse.

For example, age of onset, duration of the

disorder, previous medication use, stress, or personal
experiences could all possibly affect subjects' inability to
discontinue their medication.

Yet these correlations have

not yet been specifically addressed.

In order to determine

what, if any, external factors are associated with
unsuccessful

d~scontinuation

or relapse, further research is

necessary.
Since the cognitive factors

~ere

found to be a large

component in the treatment of PDA, one implication could be
that CBT be specifically targeted to provide the most
beneficial cognitive restructuring techniques.

In

particular, it should be aimed at altering patients'
sensitivity to bodily sensations and lowering their overall
level of anxiety.

In addition, it should work at modifying

patients' perceived levels of emotional control and their
catastrophic thinking.

This specific emphasis in cognitive

restructuring could facilitate benzodiazepine
discontinuation and reduce relapse rates.

The

specialization of CBT and the creation of similar mechanisms
would be beneficial to test in further research.
Perhaps the ASI and the HAT could be used prior to
tapering patients off medication in order to determine if
they are less sensitive to their bodily sensations and are
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experiencing a decrease in overall anxiety.

If not, they

may not be able to deal with the withdrawal symptoms which
may arise.

For example, if after 12 weeks of alprazolam and

CBT a patient is still very sensitive to his bodily
sensations and still experiencing an anxious mood, he will
not be able, or ready, to successfully discontinue
medication.

Thus, he should not be taken off the drug.

Further researCh testing the use of these two measures as
determinants or regulatory mechanisms is imperative.
Overall, the study puts

fort~

the idea that

benzodiazepine discontinuation involves more than just a
decrease in drug dosage.

Cognitive factors and level of

anxious mood seem to play a major role in predicting who can
successfully discontinue drug therapy and remain off the
medication.

Benzodiazepine treatment may stop the symptoms

of the disorder, but it does not reduce the actual fear.
When used alone, it only leads to avoidance.

Unless the

patients have a significant amount of cognitive
restructuring, via CBT or another agent, relapse is likely
to occur.

The discontinuation process must consider both

the biological and cognitive factors which occur among
patients from pre-treatment, through discontinuation, and
into the following months.

If subjects are still

experiencing and anxious mood and are fearful of their
bodily sensations, this is a strong indication of relapse

-

..
Cognitive Change
24

and unsuccessful discontinuation.

Treatment plans

t

whether

they incorporate a form of CBT or another mechanism, need to
keep these results in mind.

In conclusion, this study

targets specific cognitive features of PDA and makes
substantial suggestions for improving both benzodiazepine
discontinuation and treatment intervention.
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Appendix A

ANXIETY SENSITIVITY INDEX
Name:
Date:

Age:

Sex:

M

F_"_"_

Listed below are a number of statements describing a set of beliefs~
Please read each statement carefully and, on the 0-5 scale given, indicate
how much you think each statement is typical of you.
-----0-----------1-----------2-----------3-----------4-----------5----
Strongly
Disagree

-----'-

Moderately
Disagree

Slightly
Disagree

Slightly
Agree

Moderately
Agree

Strongly
Agree

l-

It is. important to me not to appear nervous.

2.

When I cannot keep my mind on a task, I worry that I might be
going crazy.

3.

It scares me when I feel 'shaky' (trembling) •

4.

It scares me when I feel faint.

5.

It is important to me to stay in control of my emotions.

6.

It scares me when my heart beats rapidly.

7.

It embarrasses me when my stomach growls.

8.

It scares me when I am nauseous.

9.

When I notice that my heart is beating rapidly, I worry that I
might have a heart attack.

10.

It scares me when I become short of breath.

11.

When my stomach is upset, I worry that I might be seriously ill.

12.

It scares me when I am unable to keep my mind on a task.

13.

Other people notice when I feel shaky.

14.

Unusual body sensations scare me.

15.

When I am nervous, I worry that I might be mentally ill.

_____16.

It scares me when I am nervous.
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Appendix B

NarDe:

--'-----'------------

r:ate:

_

Felow are sane'thalghts or ideas that may pass throogh peq:>le's ltli.ms when
they are nervous or frightene::l. Please rate how often each thooght occurs
to you when you are nervous. 0:> this, by writirg the apprq>riate number
fran the followi.--g scale in the space next to the thought.
1. 'lhought never oa:urs.
2. '1hcught rarely oa:urs.

3. 'lba.1ght occurs durirg half of the times I am nervoos.
4. 'Iholght usually occurs.
5. 'lhought aiways occurs when I am neJ:Voos.
I am goi.rq

to throw

uP.

I· am goi.rq to pass rot.
I must have a brain tum:>r.
I will have a heart attack.

I will choke to death.
I am goi.rq

to act foolish.

I am goi.rq blin:I.
I will

not be able to control myself.

I will hurt saneone.

I am goi.rq to have a stroke.
I am goi.rq

to go crazy.

I am goirq

to scream.

I am goirq

to babble or talk fLmny.

I will be paralyzed by fear.

other ideas rot listed (please describe an:i rate them) •

Cognitive Change
31
Appendix C

Name:
Date:_"""'--_----:~

Age:

"sex:

_

M

F

Listed bel""" are a number of statements describirg a set of beliefs.
Please read each statement carefully ani, on the 0-5 scale given, irdicate
heM nuch you think ~ statement is typical of you.
--0---1

Strongly
Disagree

----2------3-----4-----5

M:xlerately
Disagree

Slightly
Disagree

Slightly

Moderately

Agree

Strongly

Agree

Agree

_1.

I can" o:>ntrol the degree to which I react to particular
situations .

____2.

H""" well I cope with difficult situations deperx:1s on whether I
have outside help ..

.

"

---~) When I am p.rt \1l"rler

stress, I am likely to lose o:>ntrol.

- -4.

I can eaSily tum a difficult situation into a manageable one.

---...~,

My

.'

----..l

errotions seem to have a life of their own.

6.

I can deal successfully with stressful situations.

7,-

Whether I can successfully escape a fright.en:irq situation is
always a matter of chance with lI'e.

8.

I can usually influence the degree to which a situation is
~amtially~~toll'e.

__

9,~

'Ihe degree to which I react to prebleIt'S is out of my o:>ntrol.

...--lev.

'Ihe extent to which a difficult situation resolves itself has
nothi.n1 to do with my actions.

___...1],..

'Ihere is noth..ing I can do to stop anxiety once it has started.

__ J.2~

Any little th..ing can make

lI'e

uptight.

13 .

I feel like I am the victim of my em:Jtions.

14 .

I am able to control my level of anxiety.

15.

I am able to prevent myself from becorni.rq overly anxious.
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Table 1
Differences Between the A+CBT and A-Only groups at Two-weeks
Post-taper and 15-weeks Post-taper

Major Assessments

Measures

Disability
Monthly Average
Anticipatory Anxiety
Frequency (week)
Intensity

Baseline
A+CBT A-Only

1.97

1.95

2-wks post-taper
A+CBT P A-Only

.73

15-wks post-taper
A+CBT E A-Only

.04

1.43

.48

.03

2.97

.02
.29

6.80
3.50

.40
1.00

.03
.03

11.60
3.60

5.30
3.10

6.70
3.70

1.00
2.30

10.70

9.40

10.40

.10

14.60

6.30

.02

15.30

Depressed Mood
Beck Depression Inventory

7.50

7.60

4.50

.22

7.60

2.50

.04

9.90

Catastrophic Thinking
Agoraphobic Cog. Ques.

1.91

2.11

.003

2.00

1.29

.006

2.02

42.90

24.80

Anxious Mood
Hamilton Anxiety Scale

1.39

Fear of Anxiety Sensations
Anxiety Sensitivtiy Index
39.00

47.90

29.70

.09

Emotional Control
Emotional Control Ques.

44.20

55.30

.04

46.60

44.50

59.05

.08

42.00

.009

40.60

Note. A+CBT = Alprazolam plus Cognitive Behavior Therapy;
A-Only = Alprazolam Only; P = Significance Level (p<.05).

